SHRSP/A3N |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time |
controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) and controlled enrasentan content diet (1200 ppm) (for 112 days) |
Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. |
total life span |
male |
182 days-210 days |
20 |
5.0 |
% |
|
|
unspecified method |
0.0 |
0 |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) |
107935 |
3100 |
SHRSP/A3N |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time |
controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) |
Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. |
total life span |
male |
182 days-210 days |
20 |
65.0 |
% |
|
|
unspecified method |
0.0 |
0 |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) |
107934 |
3100 |
SHRSP/A3N |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time |
controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) |
Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. |
total life span |
male |
203 days-224 days |
20 |
55.0 |
% |
|
|
unspecified method |
0.0 |
0 |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) |
107113 |
3075 |
SHRSP/A3N |
ratio of deaths related to chronic hypertension to total study population during a period of time |
controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and eprosartan (60 mg/kg/d) (for 84 days) |
Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. |
total life span |
male |
168 days-189 days |
25 |
0.0 |
% |
|
|
unspecified method |
0.0 |
0 |
ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) |
107519 |
3090 |
SHRSP/A3N |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time |
controlled sodium chloride content drinking water (1 %) (for 126 days) and controlled fat content diet (24.5 %) (for 126 days) and controlled carvedilol content diet (2400 ppm) (for 126 days) |
Barone FC, etal., Pharmacology. 2007;80(2-3):166-76. doi: 10.1159/000103384. Epub 2007 Jun 4. |
total life span |
male |
203 days-224 days |
20 |
0.0 |
% |
|
|
unspecified method |
0.0 |
0 |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) |
107112 |
3075 |
SHRSP/A3NCrl |
ratio of survivors of severe albuminuria to total study population during a period of time |
controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days) |
Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. |
life span trait |
male |
161 days-175 days |
12 |
50.0 |
% |
|
|
unspecified method |
0.0 |
0 |
ratio of survivors of severe albuminuria to total study population during a period of time (CMO:0003630) |
109030 |
3083 |
SHRSP/A3N |
ratio of deaths related to chronic hypertension to total study population during a period of time |
controlled sodium chloride content drinking water (1 %) (for 63 days) and controlled fat content diet (24.5 %) (for 63 days) and vehicle control condition (for 63 days) |
Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. |
total life span |
male |
147 days-168 days |
25 |
95.0 |
% |
|
|
unspecified method |
0.0 |
0 |
ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) |
107518 |
3090 |
SHRSP/A3N |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time |
controlled sodium chloride content drinking water (1 %) (for 112 days) and controlled fat content diet (24.5 %) (for 112 days) and controlled enrasentan content diet (2400 ppm) (for 112 days) |
Willette RN, etal., J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. doi: 10.1097/00005344-200110000-00013. |
total life span |
male |
182 days-210 days |
20 |
10.0 |
% |
|
|
unspecified method |
0.0 |
0 |
ratio of deaths related to left ventricular hypertrophy to total study population during a period of time (CMO:0003810) |
107936 |
3100 |
SHRSP/A3NCrl |
ratio of survivors of severe albuminuria to total study population during a period of time |
controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then controlled SB-239063 content diet (1200 ppm) (for 35 days) |
Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15. |
life span trait |
male |
161 days-175 days |
10 |
80.0 |
% |
|
|
unspecified method |
0.0 |
0 |
ratio of survivors of severe albuminuria to total study population during a period of time (CMO:0003630) |
109031 |
3083 |